Basis of Presentation and Summary of Significant Accounting Policies (Tables)
|3 Months Ended|
Sep. 30, 2022
|Protein Sciences [Member]|
|Schedule of restructuring charges||The related first quarter of fiscal 2023 restructuring charges were recorded in the income statement as follows (in thousands):
Restructuring actions, including cash and non-cash impacts, are as follows (in thousands):
|Diagnostics and Genomics [Member]|
|Schedule of restructuring charges||
Total restructuring charges for the closure of the Exosome Diagnostics Germany facility for the year ended June 30, 2022 were recorded within operating income on the income statement as follows (in thousands):
(1)Adjustments include refinements to our estimated close down costs as well as the impacts from foreign currency exchange.
Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef